Time-to-result is not a performance metric — it is a clinical variable. The same pathogen identified in 45 minutes versus 48 hours produces completely different clinical outcomes, because the decisions that depend on that identification happen on timelines measured in hours, not days. Understanding why the 45-minute window is meaningful requires mapping time-to-result against actual clinical decision points, not against abstract accuracy benchmarks.
The clinical decision timeline for infectious disease
Consider three of the most time-sensitive infectious disease management contexts where faster pathogen identification changes clinical decisions:
Sepsis management
The Surviving Sepsis Campaign guidelines recommend initiation of appropriate antimicrobial therapy within one hour of sepsis recognition. Blood cultures are the standard method for pathogen identification, but preliminary culture results take 12–24 hours (positivity flag), with species identification and susceptibility results following 24–48 hours later. During this interval, patients receive empiric broad-spectrum therapy — typically covering Gram-positives, Gram-negatives, and sometimes anaerobes simultaneously.
Empiric therapy is appropriate when the organism is unknown. It becomes a stewardship problem when the organism is known but the result hasn't arrived yet. A patient with bacteremia caused by a methicillin-susceptible Staphylococcus aureus (MSSA) — identifiable as MSSA rather than MRSA — can be de-escalated from vancomycin to oxacillin or nafcillin, achieving better clinical outcomes and reducing selective pressure on resistant flora. That de-escalation decision requires organism identification with susceptibility context. At 48 hours, it happens if the clinician remembers to check. At 45 minutes, it can happen before the patient leaves the ICU admission assessment.
Antibiotic stewardship decisions
Antibiotic stewardship programs (ASPs) in most large hospitals operate on a 24-hour review cycle — a pharmacist or ID physician reviews culture results and contacts the ordering team with recommendations. This structure exists because culture data arrives intermittently, and the review cycle is designed around culture timelines.
If pathogen identification and provisional susceptibility context is available within the first clinical encounter — in urgent care, in the ED, in the clinic — the prescribing decision shifts from "start empiric and await cultures" to "have preliminary identification at the point of prescription." For community-acquired pneumonia, urinary tract infections, and skin and soft tissue infections — the bulk of antibiotic prescribing volume — a confident organism identification within 45 minutes substantially changes the prescribing calculus. This is where the clinical utility of rapid metagenomic sequencing is highest: not in the dramatic sepsis scenario, but in the routine outpatient antibiotic stewardship problem that drives the majority of resistance selection pressure.
Infection control response for HAIs
Hospital-acquired infections (HAIs) from multidrug-resistant organisms — carbapenem-resistant Klebsiella pneumoniae, Candida auris, Clostridioides difficile — require contact precautions from the moment of identification. Standard lab workflows identify the organism and flag resistance patterns after 48–72 hours, during which time the patient may have had multiple care contacts with healthcare workers who didn't know precautions were indicated.
A 45-minute identification window means the infection control team can be notified the same day of specimen collection. The difference between same-day contact precaution activation and next-day activation can represent dozens of care contacts and substantially altered transmission chains in a busy ward.
Why existing rapid tests don't fill the gap
PCR-based syndromic panels (multiplex respiratory panels, blood culture identification panels) achieve 1–4 hour turnaround and cover specific targets rapidly. They are genuinely useful and complement sequencing — we're not arguing they should be replaced. The limitation is the fixed target set: a 20-pathogen respiratory panel is excellent when the pathogen is one of those 20. When it isn't — a novel respiratory virus, a bacterial superinfection with an organism not on the panel, a co-infection with two agents the panel doesn't simultaneously cover — the result is "panel negative," which is clinically uninformative beyond ruling out the covered targets.
Metagenomic sequencing identifies anything present in the sample above the detection threshold. It doesn't require prior knowledge of the pathogen. For the differential diagnosis that PCR panels answer, panels are faster and cheaper. For the differential diagnosis that panels can't answer, metagenomic sequencing is the only tool that works. The clinical use case is not replacing panels — it is extending diagnostic reach to the cases where panels return negative or incomplete results.
The 45-minute target: what it requires technically
Achieving a 45-minute total time-to-result from sample to reportable call requires tight integration across the entire workflow:
- Sample-to-library: Rapid DNA extraction and library preparation in under 15 minutes. Bead-based nucleic acid capture and rapid ligation kits have made this achievable for bacterial and fungal targets from normally sterile specimens.
- Run time: 20–25 minutes of sequencing generates sufficient reads for confident identification from most clinical specimens with good input DNA quality.
- Basecalling and identification: 5–10 minutes of real-time processing running concurrently with sequencing, so the identification pipeline is running on early reads while later reads are still being generated.
- Result delivery: Formatted result (clinical summary, confidence score, AMR flag) ready for LIS transmission within 2–3 minutes of run completion.
The 45-minute target assumes no cloud upload step. Any cloud dependency in the critical path pushes this to 90–120 minutes under realistic hospital network conditions, which moves the result from "influences the same-encounter clinical decision" to "available for the next-encounter follow-up." That is a qualitatively different clinical tool.
Setting realistic expectations
The 45-minute window is achievable for well-extracted, high-quality specimens from normally sterile sites — blood, CSF, joint fluid, pleural fluid. It is harder to achieve reliably for respiratory specimens with high background DNA load, specimens with very low organism burden, or polymicrobial infections where multiple organisms require deconvolution.
We're not saying 45 minutes is a universal guarantee across all specimen types — we're saying it is an achievable and clinically meaningful target for the specific use cases where rapid identification has the highest clinical impact. The responsible way to deploy this technology is with specimen-type-specific performance characteristics, communicated clearly to the clinical users who rely on the results.
The time-to-result gap between existing culture-based methods and what's technically achievable with local nanopore sequencing is large enough to change clinical decisions for a meaningful subset of infectious disease presentations. Getting to 45 minutes requires everything to work together — sample prep, real-time calling, local compute, and immediate result delivery. The software stack is the piece that has most often been the bottleneck.